What is in the KLOW blend, how each of its four peptides is studied in the laboratory literature, how a blend is documented on its certificate of analysis, and how KLOW differs from the GLOW blend.
Part of the PeptidesATX Research Hub
KLOW is a four-peptide research blend supplied as a single lyophilised powder in a sealed glass vial, 80 mg labeled content. The composition below is the composition on the certificate of analysis: each component is measured separately against its labeled amount on every released lot.
| Component | Labeled amount |
|---|---|
| Body Protection Compound 157 | 10 mg |
| TB | 10 mg |
| GHK | 50 mg |
| KPV | 10 mg |
KLOW is the GLOW blend plus KPV: the three shared components are present at the same labeled amounts in both, and KPV is the only difference. The current lot, its purity and net content, the measured content of each component, and links to the certificate and endotoxin report are on the KLOW Blend 80mg product page.
Everything sold on this site is for laboratory research use only. This guide describes composition and the published laboratory literature; it does not describe or recommend any use of these compounds.
Body Protection Compound 157 is a synthetic 15-residue peptide whose sequence is derived from a protein found in gastric juice. The laboratory literature studies it in cell culture and animal models for cytoprotective signalling, angiogenesis-related pathways and tissue-repair models (Sikiric et al., Curr Neuropharmacol 2016; Chang et al., J Appl Physiol 2011).
TB is a 43-residue peptide of the thymosin family and a major actin-sequestering peptide in mammalian cells. It is studied for its role in actin dynamics, cell migration and wound-model biology (Goldstein et al., Trends Mol Med 2005; Malinda et al., J Invest Dermatol 1999). Its 4,963 g/mol molecular weight makes it the largest component of the blend.
GHK is the tripeptide glycyl-histidyl-lysine, supplied in this blend as its copper complex, which is how it occurs in plasma. It is studied for copper-dependent gene-expression changes and extracellular-matrix remodelling in fibroblast and skin-model systems (Pickart and Margolina, Int J Mol Sci 2018). At 50 mg it is the largest component by mass.
KPV is the tripeptide lysine-proline-valine, the C-terminal three residues of alpha-melanocyte-stimulating hormone. It is studied in intestinal epithelial and animal models for its interactions with NF-κB signalling and epithelial peptide transport (Dalmasso et al., Gastroenterology 2008; Kannengiesser et al., Inflamm Bowel Dis 2008). It is the component that distinguishes KLOW from GLOW.
The components act through non-overlapping pathways in the literature — cytoprotective signalling, actin dynamics, copper-dependent matrix biology and melanocortin-derived inflammatory signalling. A pre-mixed blend exists so a laboratory can expose one preparation to a model system and compare the result against the single-compound preparations, with the ratio between components held constant from vial to vial.
Whether the four behave differently together than apart is a question for the experiment, not a property of the product. The published work on each compound is on the compound alone; this guide makes no claim about combined effects.
One certificate of analysis covers the vial. For a blend it reports:
A separate endotoxin report accompanies most lots (the current lot's documents are linked on the product page; some early-2026 lots have none, and the report states a result without naming the assay method). The certificates do not include heavy-metal, sterility, residual-solvent or microbial testing. The lot number printed on the vial is the lot number on the certificate, so a certificate can be matched to the material in hand. Certificates for every released lot are on the COA page.
Sealed vials are kept cold, dry and protected from light, and frozen for long-term storage. The blend is supplied as lyophilised powder and is reconstituted with bacteriostatic water for laboratory handling; the reconstitution guide covers the general procedure.
| KLOW Blend 80mg | GLOW Blend 70mg | |
|---|---|---|
| Components | Body Protection Compound 157 · TB · GHK · KPV | Body Protection Compound 157 · TB · GHK |
| Labeled amounts | 10 mg · 10 mg · 50 mg · 10 mg | 10 mg · 10 mg · 50 mg |
| Fourth component | KPV, a melanocortin-derived tripeptide | None |
| Certificate | Per-component measured content on one certificate | Per-component measured content on one certificate |
The full comparison, including what the fourth component adds to a study design, is in GLOW vs KLOW: What the Fourth Component Changes.
KLOW is a four-peptide research blend: Body Protection Compound 157 (10 mg), TB (10 mg), GHK supplied as its copper complex (50 mg) and KPV (10 mg) in one lyophilised vial, 80 mg labeled content. It is the GLOW blend plus KPV. Each component is measured separately on the lot's certificate of analysis.
Body Protection Compound 157, a 15-residue synthetic peptide derived from a gastric-juice protein; TB, a 43-residue actin-binding peptide of the thymosin family; GHK, a copper-binding tripeptide supplied as its copper complex; and KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone.
The two blends share Body Protection Compound 157, TB and GHK at the same labeled amounts. KLOW adds 10 mg of KPV, which is why its labeled content is 80 mg against GLOW's 70 mg. Nothing else differs.
KPV (Lys-Pro-Val) is studied in cell and animal models for its interactions with NF-κB signalling and epithelial transport, including intestinal epithelial models. Findings are from laboratory studies; nothing here describes effects in people.
One certificate covers the vial. It reports identity and purity by UPLC/MS, net content measured against the labeled amount, and the measured content of each of the four components. A separate endotoxin report accompanies most lots (it states a result but not the assay method, and the certificate does not include heavy-metal, sterility, residual-solvent or microbial testing); the current lot's documents are linked from the product page.
Identity and purity of the blend by UPLC/MS, measured content of each component against its labeled amount, an endotoxin result, and a lot number on the vial that matches the certificate. The current lot's certificate and endotoxin report are on the product page; every released lot is on the COA page.
The current lot's certificate, endotoxin report and per-component measured content are on the product page.
KLOW Blend 80mg Certificates of Analysis GLOW vs KLOWDisclaimer: The compounds described are intended for laboratory research use only and are not approved for human or veterinary use. This article describes composition and published laboratory literature; it makes no claims about any compound's effects in people and does not describe or recommend any use, administration or dosing of any compound.